WNK2 and Alzheimer disease: In addition to coordinating with the above cyclooxygenase inhibitor to block the release of inflammatory mediators, they also improve cognitive function in AD patients by inhibiting the matrix metalloproteinase and mitogen-activated protein kinase pathways (Lu’o’ng and Nguyen, 2013).